Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

Inclusion Criteria: * Healthy adults 18-45 years of age * Subjects born in Belgium or any other country where mandatory polio vaccination is performed. * Written informed consent obtained from the subject. * Female subjects of childbearing potential may be enrolled in the study, if the subject: 1. has practiced adequate contraception for 30 days prior to vaccination, and 2. has a negative pregnancy test on the day of vaccination, and 3. has agreed to continue adequate contraception for 2 months after vaccination. Exclusion Criteria: * Participation in another clinical trial. * Any polio vaccine within 6 months before study inclusion. * Any other vaccination in the period starting 14 days before administration of study vaccine and ending 28 days after administration of the study vaccine. * Previous severe reaction after vaccination with polio vaccine. * Known hypersensitivity to one or more components of the vaccine. * Uncontrolled, clinically significant neuro-psychiatric, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic or endocrine disease. * Subjects with an history of malignant disease (cancer) * Known human immunodeficiency virus (HIV) positivity or other immune deficiency or immune suppressive treatment or auto-immune disease. For corticosteroids, a prednisone dose of \<20 mg/day, or equivalent, is allowed. Inhaled and topical corticosteroids are allowed. * Acute disease and/or fever (higher or equal to 37.5°C, measured orally) at the time of enrolment. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory tract infection) without fever may be enrolled at the discretion of the investigator. * Pregnant or lactating female. Subject who, in the opinion of the investigator, is unlikely to comply with the protocol or is inappropriate for any other reason. * Known hypersensitivity to one or more components of the vaccine. * Uncontrolled, clinically significant neuro-psychiatric, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic or endocrine disease. * Subjects with an history of malignant disease (cancer) * Known human immunodeficiency virus (HIV) positivity or other immune deficiency or immune suppressive treatment or auto-immune disease. For corticosteroids, a prednisone dose of \<20 mg/day, or equivalent, is allowed. Inhaled and topical corticosteroids are allowed. * Acute disease and/or fever (higher or equal to 37.5°C, measured orally) at the time of enrolment. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory tract infection) without fever may be enrolled at the discretion of the investigator. * Pregnant or lactating female. * Subject who, in the opinion of the investigator, is unlikely to comply with the protocol or is inappropriate for any other reason.